Related Experiment Videos

Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors

Mark W Kieran1, Charles W M Roberts, Susan N Chi

  • 1Director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Pediatric Hematology/Oncology, Boston, MA 02215, USA. mark_kieran@dfci.harvard.edu

Pediatric Blood & Cancer
|September 22, 2012
PubMed
Abstract

Insights

Rhabdoid tumors, including atypical teratoid/rhabdoid tumors (AT/RT), show limited actionable mutations beyond SMARCB1. This suggests distinct pediatric tumor mechanisms may require novel therapeutic strategies focusing on developmental and epigenetic pathways.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Rhabdoid tumors (RTs), including atypical teratoid/rhabdoid tumors (AT/RT), are aggressive neoplasms with poor prognosis affecting the central nervous system, kidneys, and soft tissues.
  • Effective targeted therapy for RTs necessitates advanced methods for detecting actionable mutations.

Purpose of the Study:

  • To comprehensively analyze mutations in oncogenes and tumor-suppressor genes in RTs.
  • To identify potential therapeutic targets for these highly malignant pediatric tumors.

Main Methods:

  • Utilized OncoMap, a mass spectrometry-based method, to screen 25 RTs with known SMARCB1/INI1 alterations.
  • Assessed 983 distinct mutations across 115 key oncogenes and tumor-suppressor genes.

Main Results:

  • Confirmed SMARCB1/INI1 alterations as a primary genetic driver.
  • Identified a single activating NRAS mutation in one tumor.
  • Observed a lack of oncogenic mutations in all other tested genes, including canonical cancer pathways.

Conclusions:

  • The genetic landscape of RTs is distinct from adult cancers, characterized by a paucity of mutations in common oncogenic pathways.
  • These findings suggest that current targeted therapies may have limited efficacy.
  • Future therapeutic strategies should explore developmental and epigenetic pathways for treating these aggressive pediatric tumors.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...